RTS has won approval in Europe as the world's first malaria vaccine. This is a
major step towards prevention of a disease that kills more than half a million
people worldwide every year. This week, the EMA concluded that the vaccine
should be used for immunization of children in Africa of age 6 weeks to 17
months along with other protective measures against malaria such as
insecticides and bed nets. Later this year, the WHO is going to review evidence
for the vaccine and decide whether to recommend its use. The deadliest of the
malarial parasite is the Plasmodium falciparum which is what the RTS,S vaccine
targets. It works by inducing an immune response in the body. However, one
point to be noted is that in clinical trials, the vaccine has not proved
effective enough to be used alone.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources